---
title: "Lipid droplets regulate macrophage resolution and phagocytic capacity"
id: "frontiers-in-immunology-4-lipid-droplets-as-the-metabolic-switch-of-macrophage-resolution"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-lipid-droplets-as-the-metabolic-switch-of-macrophage-resolution"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1992651"
published_at: "2026-11-12T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Lipid droplets regulate macrophage resolution and phagocytic capacity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-lipid-droplets-as-the-metabolic-switch-of-macrophage-resolution
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1992651)
- **Published At:** 2026-11-12T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Macrophage lipid handling determines whether inflammation resolves or becomes chronic; **lipid droplets** (LDs) store neutral lipids and buffer free cholesterol and fatty acids. - The review links LD dynamics directly to **efferocytosis**, with successful clearance promoting cholesterol efflux and pro-resolving signaling that reinforce subsequent engulfment. - Pro-inflammatory macrophages accumulate LDs; investigators reported that this accumulation impairs recognition, engulfment, and digestion at multiple stages of efferocytosis. - The proteomic coat (PLIN2/PLIN3) and a neutral-lipase relay (ATGL➔HSL➔MAGL) plus lysosomal acid lipase and cholesterol-ester enzymes set droplet turnover and thus macrophage capacity. - Authors noted that some LD formation is cytoprotective (early atherosclerotic lesions) but becomes maladaptive when turnover or efflux stalls, creating a self-reinforcing loop of failed clearance and lipid burden. - Nitric oxide and inflammatory signaling redirect metabolism toward glycolysis, inhibit LXRα and ABCA1, and favor LD accumulation; soluble Mer release via ADAM17 reduces MerTK-mediated recognition. - Mechanical effects of LDs can displace apical actomyosin and delay phagosome closure; ER stress from free-cholesterol dysregulation engages ATF4/TRIB3 and impairs Rab27a-dependent closure. - Lipophagy, autophagy, and LC3-associated phagocytosis are progressively impaired with chronic lipid loading, reducing digestion and host-defense phagocytosis. - The review emphasizes druggability of several enzymes but also cautions that current inhibitors are tool-grade, off-target risks exist, and macrophage-selective strategies will be required. - Gaps recorded by the authors include tissue- and niche-specific LD biology, the systemic neural control of the lipase switch, and the translational challenge of selectively targeting macrophage lipase machinery.
## Clinical Analysis & Structured Key Points
Frontiers | Lipid droplets as the metabolic switch of macrophage resolution MINI REVIEW article Front. Immunol. , 12 November 2026 Sec. Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1992651 Published in Frontiers in Immunology Autoimmune Disorders 7 impact factor 11.3 citescore Part of a Research Topic Macrophage Immunometabolism and Immune Resolution Across Different Tissue Niches Submission open 4045 views 1 articles Editor & Reviewers Edited by G H Guanglong He Reviewed by J H Jun Huang Outline Figures and Tables Figure 1 View in article MINI REVIEW article Front. Immunol. , 12 November 2026 Sec. Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1992651 Lipid droplets as the metabolic switch of macrophage resolution M L Moses Lee 1,2 M S Myoungsun Son 1,3 * 1. Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States 2. CUNY School of Medicine, New York, NY, United States 3. Department of Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States See more Article metrics View details Abstract Macrophages play a key role in cellular immunity and metabolism, and their lipid handling is a crucial determinant of whether inflammation resolves or becomes chronic. Lipid droplets (LDs) are now recognized as active organelles that regulate free cholesterol and fatty acids and influence immune signaling. This review examines the reciprocal relationship between LDs and efferocytosis, the clearance of apoptotic cells. Successful efferocytosis promotes cholesterol efflux and pro-resolving signaling, thereby reinforcing the capacity for subsequent clearance. Conversely, pro-inflammatory macrophages accumulate LDs; disrupted lipid balance impairs efferocytosis at multiple stages. We propose that LD coat proteins and lipases regulate droplet turnover and, consequently, macrophage engulfment capacity. We further suggest that this principle extends beyond efferocytosis, as LD turnover may supply lipid and membrane components that support the membrane remodeling and cytoskeletal processes required for large-particle engulfment. Importantly, this switch is bidirectional and context-dependent rather than a simple rule that lipid-droplet accumulation is harmful: whether droplet build-up is adaptive or maladaptive depends on inflammatory phase, polarization state, and tissue niche. Together, these observations position the LD enzyme and coat protein machinery as potential regulators of macrophage engulfment capacity. 1 Introduction Macrophages are central components of the innate immune system that maintain homeostasis, and beyond clearing pathogens, they remodel their environment by regulating metabolic pathways, with recent studies highlighting lipid metabolism as a key mechanism ( 1 – 3 ). Macrophages arise from developmentally distinct sources: yolk-sac-derived tissue-resident populations and circulating monocytes, and their phenotype is shaped as much by ontogeny and niche as by the immediate cytokine milieu ( 4 ). Nonetheless, the M1 (pro-inflammatory) and M2 (pro-resolving) paradigm remains mechanistically informative and therapeutically actionable: the M1/M2 imbalance tracks with remission and flare in systemic lupus erythematosus (SLE) and rheumatoid arthritis and with divergent contributions to atherosclerotic plaque stability, allergic airway inflammation, and transplant rejection ( 5 , 6 ). Lipid droplets (LDs) are organelles bounded by a phospholipid monolayer and a coat of structural and regulatory proteins, enclosing a neutral-lipid core of triacylglycerols (TAGs) and cholesterol esters (CEs). Their core function is to store free cholesterol and fatty acids as neutral lipids, protecting cells from otherwise lipotoxic species ( 7 , 8 ). Altered intracellular lipid metabolism within immune cells has been characterized in several metabolic disorders and often results in LD accumulation ( 9 , 10 ). This accumulation occurs when lipid influx exceeds disposal or when lipid disposal fails. Accumulated LDs thus serve as hallmarks of impaired cholesterol efflux, ER stress, or failed resolution of inflammation ( 11 ). Because LDs respond to their environment, understanding their mechanistic relationship with macrophage function may offer important insights into pathogenic inflammation. Lipid-loaded macrophages are a hallmark of several metabolic diseases ( 12 ). Across atherosclerosis, infection, cancer, and inflammation, LDs act as a hub of macrophage dysfunction, and among the functions most closely tied to lipid regulation is efferocytosis, the engulfment of apoptotic cells and debris ( 13 , 14 ). Efferocytosis-induced proliferation expands the pool of resolving macrophages ( 15 ). Uncleared apoptotic cells, common in autoimmune conditions such as SLE, undergo secondary necrosis to expose damage associated molecular patterns (DAMPs), nuclear autoantigens, and nucleic acids that drive anti-nuclear autoantibodies and type I interferon responses ( 16 ). Genetic ablation of the bridging molecule MFG-E8 or of phosphatidylserine-recognition machinery causes failed clearance and a lupus-like syndrome in mice ( 17 , 18 ). When efferocytosis fails, LDs lack the fuel to promote pro-resolving signaling and manage accumulated lipids. Because lipid-loaded macrophages are themselves impaired in efferocytosis, failed clearance and lipid burden compound one another in a self-reinforcing loop ( 14 ). The LD–efferocytosis relationship is thus a circuit that either promotes pro-resolving states that reinforce clearance or inverts into a cycle of lipid accumulation and failed efferocytosis ( 19 ). In early atherosclerotic lesions and in macrophages re-esterifying sterol load, droplet formation is an adaptive, cytoprotective response that sequesters lipotoxic free cholesterol and fatty acids and can even restrain inflammatory signaling. It becomes maladaptive only when droplet turnover fails and clearance stalls in advanced lesions ( 20 , 21 ). 2 Regulation of lipid metabolism by efferocytosis Apoptotic cells carry substantial lipid cargo in their membranes and droplets. Once engulfed, this cargo is processed by lysosomes to free fatty acids and cholesterol that are stored in LDs, used for membrane biosynthesis, or — directed toward β-oxidation. A single efferocytic event can nearly double the phagocyte’s plasma-membrane cholesterol, and the cell must rapidly esterify, efflux, or oxidize this load to avoid toxicity ( 22 ). Successful efferocytosis also reinforces subsequent clearance: cholesterol from the ingested cell generates LXR ligands, and LXR induces both MerTK and ABCA1, simultaneously amplifying recognition and providing an efflux route ( 23 ). In parallel, efferocytic cargo stimulates PPARδ and PPARγ, triggering the production of pro-resolving factors (C1q, TGF-β, IL-10) and biosynthesis of specialized pro-resolving mediators (SPMs), linking each engulfment to the larger resolution process ( 24 , 25 ). The direction of this circuit is set not by bulk lipid content but by the proteins that coat and remodel the droplet. Perilipin coat proteins (PLIN2, PLIN3) gate lipase access, while a neutral-lipase relay [ATGL➔ HSL➔MAGL; ( 26 , 27 )] and the lysosomal acid lipase/lipophagy arm determine whether stored lipid is mobilized for efflux and oxidation or allowed to accumulate; a parallel cholesterol-ester cycle (ACAT1/SOAT1 esterification; NCEH1/LAL hydrolysis) sets the free-cholesterol set-point that governs the ER-stress brake on phagosome closure. These enzymes act as molecular switches within the resolution circuit and, unlike transcription factors, several are directly druggable. The two neutral lipases most attractive as levers on the droplet-lipase relay, ATGL and HSL, are served only by tool-grade inhibitors: the ATGL inhibitor Atglistain ( 28 ) and the HSL inhibitor BAY 59-9435 ( 29 ). The enzymes flanking the cholesterol arm (MAGL, ACAT1/SOAT1, LAL) have been structurally solved, providing a foundation for inhibitors ( 30 – 32 ). These components carry comparable regulatory weight. ATGL sets the initial rate of droplet triacylglycerol mobilization and gates entry into the relay with its co-activator ABHD5/CGI-58 ( 27 , 33 ). In the opposite direction, DGAT1/2-driven re-esterification buffers incoming fatty acids back into droplets and protects the macrophage from lipotoxicity and ER stress during periods of high lipolytic flux ( 34 ). The PLIN2/PLIN3 coat sets in when any of these lipases gains access to the core ( 35 , 36 ). Druggability, however, does not guarantee straightforward therapeutic translation, as these lipases act broadly across tissues rather than selectively within macrophages. Pharmacologically activating neutral lipolysis to mobilize macrophage LDs therefore risks elevating circulating free fatty acid levels and inducing lipotoxicity in off-target tissues ( 37 ). This becomes especially of concern under inflammatory conditions, where impaired ABCA1/ABCG1-mediated cholesterol efflux may be unable to accommodate the resulting lipid flux, potentially exacerbating rather than resolving lipid overload ( 22 , 38 ). Utilizing the lipase relay as a therapeutic route will require selective approaches for macrophages instead of broad, global enzyme modulation. HSL offers one experimentally worked example of how a single node in this relay can bias the whole circuit toward resolution: HSL activity has recently been shown to support efficient efferocytosis and acquisition of an M2-like, resolution-competent phenotype, with its loss shifting macrophages toward a pro-inflammatory, clearance-deficient state ( 19 ). 3 Inflammation drives lipid droplet accumulation Pro-inflammatory stimuli, such as IFNγ and TLR ligands drive M1 activation of macrophages. This acts as a switch that inverts the macrophage–LD relationship by driving a metabolic shift from oxidative phosphorylation toward glycolysis, promoting lipid accumulation and LD formation ( 12 ). This metabolic shift is initiated by the activation of iNOS in response to inflammatory stimuli, resulting in the production of NO. NO plays a central role in lipid accumulation, primarily through two pathways. First, NO targets aconitase 2, interrupting the TCA cycle to impair the mitochondrial ETC complex ( 39 , 40 ). This limits a major route of intracellular fatty-acid catabolism and redirects fatty acids toward esterification into TAGs and CEs, promoting LD formation. Second, NO suppresses cholesterol efflux by promoting the degradation of LXRα, down regulating the cholesterol transporter ABCA1 and thus promoting LD accumulation ( 41 ) ( Figure 1 ). Critically, because ABCA1 and MerTK are co-induced by LXR ( 23 ), NO-driven LXRα loss simultaneously compromises both the efflux pathway and the recognition receptor. Importantly, LD accumulation itself may not be the principal driver of macrophage dysfunction, but rather a consequence and indicator of disrupted lipid homeostasis that ultimately affects core macrophage functions. Figure 1 Flowchart graphic comparing pro-resolving and pro-inflammatory macrophages, detailing molecular pathways. The left green section outlines cholesterol efflux and anti-inflammatory mediators, while the right red section shows lipid droplet accumulation, nitric oxide signaling, and failed clearance mechanisms. A central yellow box represents a metabolic switch influencing both states. 4 Lipid loading impairs efferocytosis Efferocytosis is closely linked to LD regulation, and when lipid metabolism becomes dysregulated, macrophages show impaired capacity to phagocytose and digest targets. Such macrophages can become trapped in a self-reinforcing cycle: defective efferocytosis prevents clearance of apoptotic cells that would otherwise activate pathways reducing lipid burden, while uncleared DAMPs perpetuate the inflammatory signals that caused the dysfunction. Lipid metabolism thus regulates efferocytosis across multiple stages. Recognition. Apoptotic-cell recognition depends on surface receptors, prominently the TAM-family receptor MerTK ( 42 ). Lipid and oxidative stress impair MerTK directly: hypercholesterolemia and oxidized phospholipids activate ADAM17, which cleaves MerTK to release soluble Mer. Soluble Mer both eliminates the surface receptor and competitively inhibits residual MerTK, suppressing efferocytosis and pro-resolving mediator biosynthesis ( 43 ). Plasma soluble Mer is elevated in active SLE, linking recognition-receptor impairment to autoimmune disease activity ( 44 ). Engulfment. Once a target is recognized, the macrophage must physically engulf it, and here is where LDs impose a mechanical constraint. LDs are relatively rigid compared with the surrounding cytoplasm and can displace the apical actomyosin cytoskeleton; because apoptotic engulfment is initiated at the apical surface, such displacement may directly suppress phagocytic capacity ( 45 ). Notably, this suppression was reversible by mechanical compression or stretching, suggesting a tunable biophysical state rather than a fixed consequence of lipid accumulation — implying that mobilizing droplet lipids could relieve the constraint. Beyond mechanics, excess free cholesterol inhibits ACAT1, the enzyme that esterifies free cholesterol (FC) for safe LD storage. When this buffering is inhibited, unesterified FC accumulates in membranes and drives ER stress. LDs are not static depots but undergo continuous hydrolysis, releasing FC that moves to the ER for re-esterification — a dynamic reservoir ( 46 ). When FC release is coupled with impaired esterification, ER stress is amplified. ER stress impairs efferocytosis via ATF4, which upregulates TRIB3 and downregulates Rab27a, delaying phagosome closure ( 47 ). The PERK–CHOP arm is an established driver of macrophage apoptosis and defective efferocytosis in advanced plaques ( 48 ). LD biogenesis also consumes ER membrane, which may compete with phagosome formation and perturb RAC1 translocation and GTPase activity ( 49 ). The engulfment stage thus appears particularly sensitive to lipid dysregulation. Digestion/lipophagy. After engulfment, the macrophage must catabolize the newly acquired lipid load, in part through lipophagy — the autophagic delivery of LDs to lysosomes, where lysosomal acid lipase hydrolyzes CE to generate FC for ABCA1-mediated efflux ( 46 ). This pathway is progressively impaired under chronic lipid loading: autophagy becomes dysfunctional in advanced atherosclerotic macrophages. Atg5 deficiency promotes NLRP3 inflammasome activation, oxidative stress, and defective efferocytosis, closing the loop between failed digestion and sustained inflammation ( 50 , 51 ). Thus, lipid loading can impair all three stages of efferocytosis through mechanisms involving LD-associated enzymes and lipid-handling pathways. These mechanisms are not confined to foam cells alone. Lipid- and LD-rich macrophages can arise whenever supply exceeds disposal, and this is prominently shown in adipose tissue macrophages (ATMs). In obesity, dying adipocytes are surrounded by macrophages to form “crown-like structures,” which internalize the released lipids to form a lipid-associated macrophage phenotype, marked by TREM2 ( 52 , 53 ). The lipid overload that impairs apoptotic cell uptake also appears to blunt clearance within this context. Defective removal of the dying adipocytes will sustain the crown-like structures, DAMP release, and even chronic inflammation that can result in insulin resistance ( 54 ). The protective-to-pathogenic perspective of LD accumulation is seen to recur in a different tissue niche to reinforce our central claim that LD biology is set by environmental context. 5 From efferocytosis to general phagocytosis Receptor-mediated recognition, actin-driven cup formation, and lysosomal digestion are not unique to apoptotic-cell uptake; they constitute the conserved core of large-particle phagocytosis, whether the target is a bacterium, a fungal particle, an immune complex, or debris ( 55 ). The LD–lipolysis machinery reviewed here may therefore regulate phagocytic capacity more broadly, and emerging evidence supports this notion. It must be noted, however, although the uptake machinery converges, the two processes diverge sharply in their downstream immunologic consequences: efferocytosis is typically coupled to tolerogenic, pro-resolving signaling (e.g., IL-10 and TGF-β induction, LXR/PPAR activation, and suppression of NF-κB) that restrains inflammation and guards against autoimmunity, whereas phagocytosis of pathogens engages pattern-recognition receptor signaling that favors pro-inflammatory, antimicrobial programs (e.g., NF-κB and inflammasome activation) ( 56 , 57 ). Thus, the same core LD-lipolysis machinery may support resolution or host defense depending on the phagocytic context. Membrane supply is the clearest point of convergence. Engulfing a large particle can require a several-fold expansion of surface area at the phagocytic cup, drawn from endomembrane and lipid stores. LDs may serve as a mobilizable reservoir for this process. Therefore, when lipolysis is blocked and lipid is sequestered as inert neutral lipid, the phagocyte becomes substrate-limited for cup closure ( 45 , 49 ). The cytoskeletal machinery is shared as well: Rho-family GTPases (RAC1, CDC42, RhoA) orchestrate actin polymerization at the cup in both efferocytosis and Fcγ-/complement-receptor phagocytosis. Because ER-membrane consumption during LD biogenesis perturbs RAC1 translocation and GTPase activity, lipid overload may constrain the actin machinery common to these pathways rather than affecting efferocytosis alone. Degradation and membrane recycling complete the parallel. LC3-associated phagocytosis (LAP) serves both apoptotic cells and microbes and draws on autophagy machinery overlapping with lipophagy ( 58 ). Because chronic lipid accumulation inhibits autophagy and lipophagy ( 50 ), it is likely to impair LAP-dependent clearance of both cargoes — linking droplet dysfunction to compromised host defense. Consistent with this, foam cells and lipid-laden macrophages generally show reduced phagocytic activity, including diminished bacterial uptake and killing ( 59 ). The neutral-lipase pathway also supplies eicosanoids and SPMs through MAGL-controlled arachidonic-acid release, which can modulate phagocytic-receptor expression ( 60 ). The arrangement of LD lipids also affects nearby immune cells, influencing overall tissue inflammation. Macrophages can export their lipid state directly. Through contact-dependent trogocytosis, LPS-activated macrophages transfer fatty acids and CD36 to adjacent natural killer cells. This lipid load suppresses mTORC1 signaling and IFNγ production, and blocking macrophage fatty-acid synthesis restores NK-cell effector function ( 61 ). The LD can also become an instrument of tissue damage in the autoimmune settings considered above. In the lipid-rich rheumatoid synovium, free fatty acids drive tissue-invading CD4+ T cells to sequester the pore-forming protein gasdermin D and the acyltransferase zDHHC5 onto lipid droplets. These droplets then translocate to the plasma membrane and rupture it, causing lytic, pyroptotic cell death that releases immunogenic contents and perpetuates inflammation ( 62 ). 6 Future directions and perspectives The connection between lipid metabolism/LDs and efferocytosis remains largely unexplored across tissue environments and macrophage phenotypes. A further gap is that the switch is framed here as cell-intrinsic, whereas its most likely physiological control is systemic neural regulation. The sympathetic arm supplies the canonical trigger for neutral lipolysis: catecholamines acting through β-adrenergic receptors drive the Gs–cAMP–PKA cascade that phosphorylates HSL and PLIN and promotes HSL translocation to the droplet ( 63 ). That m
## Related Clinical Research

- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [Immuno-metabolic Crosstalk in Osteoarthritis: Mechanisms and Therapeutic Insights](https://medichelpline.com/clinical-feed/frontiers-in-immunology-18-immuno-metabolic-crosstalk-in-osteoarthritis-from-mechanisms-to-therapies.md)
- [ZnT8 autoantibodies are common in rheumatoid arthritis and identify synovial lining fibroblasts as](https://medichelpline.com/clinical-feed/medrxiv-12-diabetes-related-antibody-signature-highlights-znt8-as-a-novel-antigenic-target.md)
- [Endocrine Society Roadmap: Research Priorities and Gaps in Obesity Science](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-scientific-statement-provides-research-roadmap-for-what-s.md)
- [Preload meal size, postprandial acyl ghrelin, LEAP2, insulin, glucose and appetite in adults witho](https://medichelpline.com/clinical-feed/medrxiv-2-relationships-between-increasing-pre-load-meal-size-post-prandial-acyl-ghrelin.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.